Alimentary Pharmacology & Therapeutics

Review article: fructose malabsorption and the bigger picture
pp. 349-363(15)
Authors: GIBSON, P. R.; NEWNHAM, E.; BARRETT, J. S.; SHEPHERD, S. J.; MUIR, J. G.

Review article: glucagon-like peptide 2 - current applications and future directions
pp. 365-372(8)
Authors: WALLIS, K.; WALTERS, J. R. F.; FORBES, A.

Systematic review: oral bowel preparation for colonoscopy
pp. 373-384(12)
Authors: BELSEY, J.; EPSTEIN, O.; HERESBACH, D.

Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease
pp. 385-392(8)
Authors: GATTA, L.; VAIRA, D.; SORRENTI, G.; ZUCCHINI, S.; SAMA, C.; VAKIL, N.

Meta-analysis: ondansetron for vomiting in acute gastroenteritis in children
pp. 393-400(8)
Authors: SZAJEWSKA, H.; GIERUSZCZAK-BIAŁEK, D.; DYLĄG, M.

GI Epidemiology: nutritional epidemiology
pp. 401-407(7)
Author: KELEMEN, L. E.

Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial
pp. 409-418(10)
Authors: HINOJOSA, J.; GOMOLLÓN, F.; GARCÍA, S.; BASTIDA, G.; CABRIADA, J. L.; SARO, C.; CEBALLOS, D.; PEÑATE, M.; GASSULL, M. A.

Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results
pp. 419-427(9)
Authors: LAZZERINI, M.; MARTELOSSI, S.; MARCHETTI, F.; SCABAR, A.; BRADASCHIA, F.; RONFANI, L.; VENTURA, A.

Combined type-1 plasminogen activator inhibitor and NOD2/CARD15 genotyping predicts complicated Crohn's disease behaviour
pp. 429-440(12)
Authors: ALVAREZ-LOBOS, M.; AROSTEGUI, J. I.; SANS, M.; TASSIES, D.; PIU, J.; REVERTER, J. C.; PIQUE, J. M.; YAGÜE, J.; PANÉS, J.

Determining the proximal extent of ulcerative colitis: white cell scan correlates well with histological assessment
pp. 441-446(6)
Authors: SUBRAMANIAN, V.; BANERJEE, A.; BEHARRY, N.; FARTHING, M. J. G.; POLLOK, R. C. G.

The changing incidence of oesophageal and gastric adenocarcinoma by anatomic sub-site
pp. 447-453(7)
Authors: CRANE, S. J.; RICHARD LOCKE, G.; HARMSEN, W. S.; DIEHL, N. N.; ZINSMEISTER, A. R.; JOSEPH MELTON, L.; ROMERO, Y.; TALLEY, N. J.

Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication
pp. 455-461(7)
Authors: YANG, H.-B.; CHENG, H.-C.; SHEU, B.-S.; HUNG, K.-H.; LIOU, M.-F.; WU, J.-J.

Efficacy of tegaserod for functional constipation in Chinese subjects: a randomized double-blind controlled trial in a single centre
pp. 463-469(7)
Authors: ON CHAN, A. O.; MO HUI, W.; LEUNG, G.; HU, W. H. C.; LAM, S. K.; WONG, B. C. Y.

An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis
pp. 471-476(6)
Authors: JONES, D. E. J.; NEWTON, J. L.

The Short-Form Leeds Dyspepsia Questionnaire validation study
pp. 477-486(10)
Authors: FRASER, A.; DELANEY, B. C.; FORD, A. C.; QUME, M.; MOAYYEDI, P.

Consequences of frequent nocturnal gastro-oesophageal reflux disease among employed adults: symptom severity, quality of life and work productivity
pp. 487-500(14)
Authors: DUBOIS, R. W.; AGUILAR, D.; FASS, R.; ORR, W. C.; ELFANT, A. B.; DEAN, B. B.; HARPER, A. S.; YU, H.-T.; MELMED, G. Y.; LYNN, R.; SINGH, A.; TEDESCHI, M.

Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers
pp. 501-510(10)
Authors: NORRIS, V.; BAISLEY, K.; DUNN, K.; WARRINGTON, S.; MOROCUTTI, A.

Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn
pp. 511-517(7)
Authors: WARRINGTON, S.; BAISLEY, K.; LEE, D.; LOMAX, K.; DELEMOS, B.; BOYCE, M.; MOROCUTTI, A.

C-reactive protein polymorphism and Crohn's disease
pp. 519-519(1)
Authors: Szalai, A. J.; Alarcón, G. S.

C-reactive protein polymorphism and Crohn's disease: authors' reply
pp. 520-521(2)
Authors: Brand, S.; Crispin, A.